Bright Minds Biosciences Inc. (DRUG) Insider Trading Activity

NASDAQ$75.97
Market Cap
$591.58M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
555 of 888
Rank in Industry
325 of 508

DRUG Insider Trading Activity

DRUG Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
Sells
$0
0

Related Transactions

About Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Insider Activity of Bright Minds Biosciences Inc.

Over the last 12 months, insiders at Bright Minds Biosciences Inc. have bought $0 and sold $0 worth of Bright Minds Biosciences Inc. stock.

On average, over the past 5 years, insiders at Bright Minds Biosciences Inc. have bought $7.23M and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 184,331 shares for transaction amount of $4M was made by Cormorant Asset Management, LP (10 percent owner) on 2024‑11‑04.

List of Insider Buy and Sell Transactions, Bright Minds Biosciences Inc.

2024-11-04PurchaseCormorant Asset Management, LP10 percent owner
184,331
1.3083%
$21.70
$4M
-28.71%
2024-10-16PurchaseCormorant Asset Management, LP10 percent owner
50,000
0.3836%
$23.46
$1.17M
+25.14%
2024-10-15PurchaseCormorant Asset Management, LP10 percent owner
372,591
0.6743%
$5.53
$2.06M
-6.46%
Total: 3

Insider Historical Profitability

<0.0001%
Cormorant Asset Management, LP10 percent owner
1059331
13.6038%
$80.48M30
<0.0001%

Historical Insider Profitability vs. Competitors

$3,611,891
113
13.40%
$605.89M
$24,857,912
21
-35.40%
$711.12M
$46,858,891
18
-11.58%
$585.02M
$3,556,951
18
9.64%
$523.09M
$59,102,045
17
8.52%
$685.28M
$7,254,955
14
20.70%
$619.87M
$92,357,691
12
87.24%
$712.26M
$19,167,169
10
28.48%
$527.04M
$75,069,528
10
19.77%
$526.24M
$140,543,039
10
0.77%
$598.05M
$11,541,901
10
8.07%
$681.35M
$49,165,200
7
12.92%
$639.94M
$94,000,000
7
-20.84%
$644.42M
$79,246,559
5
-27.73%
$507.97M
$1,746,565
4
-29.05%
$575.18M
$58,352
4
-43.78%
$508.58M
$10,104,842
3
5.45%
$522.59M
Bright Minds Biosciences Inc.
(DRUG)
$7,234,370
3
-3.34%
$591.58M
$3,850,000
1
-51.32%
$522.94M

DRUG Institutional Investors: Active Positions

Increased Positions40+102.56%1M+23.76%
Decreased Positions14-35.9%524,174-9.87%
New Positions16New593,267New
Sold Out Positions2Sold Out74,623Sold Out
Total Postitions65+66.67%6M+13.89%

DRUG Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Janus Henderson Group Plc$95,617.0014.32%1.15M00%2025-09-30
Cormorant Asset Management, Lp$88,412.0013.24%1.06M00%2025-09-30
Vivo Capital, Llc$41,865.006.27%501,617+250,045+99.39%2025-09-30
Commodore Capital Lp$41,730.006.25%500,00000%2025-09-30
Perceptive Advisors Llc$37,498.005.62%449,290+28,600+6.8%2025-09-30
Adage Capital Partners Gp, L.L.C.$33,029.004.95%395,743+195,743+97.87%2025-09-30
Braidwell Lp$25,346.003.8%303,685+303,685New2025-09-30
Blackrock, Inc.$19,539.002.93%234,118+24,441+11.66%2025-09-30
Morgan Stanley$16,097.002.41%192,866+30,797+19%2025-09-30
Sio Capital Management, Llc$15,921.002.38%190,764-321,574-62.77%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.